Structure of virantmycin, a novel antiviral antibiotic

Asymmetric synthesis of functionalized 1,2,3,4-tetrahydroquinolines

[reaction: see text] Highly enantioselective rhodium-catalyzed asymmetric hydrogenation (>98% ee) and Sharpless epoxidation (>90% ee) of o-nitrocinnamyl substrates lead to intermediates that can be transformed into tetrahydroquinoline derivatives. Starting materials are produced in high-yielding Heck reactions of an o-nitroaryl iodide and alpha-acetamidoacrylate or methyl acrylate.

Natural Products as Antiviral Agents

Since the ancient times, natural products have served as a major source of drugs. About fifty percent of today's pharmaceutical drugs are derived from natural origin. Interest in natural products as a source of new drugs is growing due to many factors that will be discussed in this article. Viruses have been resistant to therapy or prophylaxis longer than any other form of life. Currently, there are only few drugs available for the cure of viral diseases including acyclovir which is modeled on a natural product parent. In order to combat viruses which have devastating effects on humans, animals, insects, crop plants, fungi and bacteria, many research efforts have been devoted for the discovery of new antiviral natural products. Recent analysis of the number and sources of antiviral agents reported mainly in the annual reports of medicinal chemistry from 1984 to 1995 indicated that seven out of ten synthetic agents approved by FDA between 1983-1994, are modeled on a natural product parent. It has been estimated that only 5-15% of the approximately 250,000 species of higher plants have been systematically investigated for the presence of bioactive compounds while the potential of the marine environment has barely been tapped. The aim of this review is to provide an overview on the central role of natural products in the discovery and development of new antiviral drugs by displaying 340 structures of plant, marine and microbial origin that show promising in vitro antiviral activity.

A simple convergent approach to the synthesis of the antiviral agent virantmycin

[structure: see text] The antiviral agent (+/-)-virantmycin has been synthesized from two simple building blocks (2 and 3) in eight steps, as outlined in Scheme 2.